Switzerland has done something no other European country has: written a statutory basis for scientifically evaluated, regulated cannabis sales and then actually used it. Article 8a of the Narcotics Act permits time-limited, locality-bound pilot trials, and the Federal Office of Public Health has authorised a series of them since 2023, testing pharmacy sales, specialist shops, non-profit and state-run models against control groups. Outside those trials, non-medical cannabis above 1 percent THC remains prohibited, while low-THC CBD products are a normal consumer market and medical cannabis has been prescribable without federal exemption since 2022.
Prohibition with a statutory research carve-out. Regulated adult sale exists only inside authorised pilot trials, each geographically limited, capped in size and time-limited. The enabling framework itself is time-limited, which means Switzerland faces a decision point rather than an open-ended pilot regime.
Since August 2022, physicians may prescribe medical cannabis without needing a federal exemption, which shifted the bottleneck from authorisation to reimbursement and prescriber confidence. Swissmedic licenses cultivation, manufacture and trade in cannabis for medical use, and reimbursement is not automatic.
Non-medical use of cannabis above 1 percent THC remains prohibited. Possession of a small quantity for personal use is not punishable, and adult consumption is typically dealt with by a fixed fine. Legal purchase is possible only as a participant in an authorised pilot trial, within that trial's rules and locality.
Cannabis products below 1 percent THC fall outside narcotics control, which is why Switzerland has a comparatively large and long-established CBD sector covering flower, extracts and consumer goods, subject to food, tobacco-substitute and product-safety rules.
Cultivating cannabis above 1 percent THC for non-medical use is prohibited. Low-THC hemp cultivation is permitted subject to sector rules. Pilot trial participation does not confer a cultivation right.
There is no cannabis social club framework. Distribution models are instead defined per pilot trial and have included pharmacy dispensing, specialist retail, non-profit structures and, in one authorised trial, home delivery.
Advertising narcotics is prohibited, and pilot trial products may not be advertised to the general public. Participant communications are governed by each trial's authorisation conditions.
The FOPH has authorised eight Article 8a pilot trials since the first began in 2023, spanning several cantons and market models, with the most recent adding home delivery to the designs being tested. Each trial is capped at 5,000 participants and five years, with one possible two-year extension, and the enabling legislation runs from 15 May 2021 to 14 May 2031.
30 Jan 2023
The first Article 8a trial starts supplying participants under FOPH authorisation, opening a sequence of studies across Swiss cities and cantons testing different regulated-sale models against control groups.
1 Aug 2022
A reform of the Narcotics Act removes the exemption requirement for medical cannabis prescriptions, moving Switzerland from case-by-case federal authorisation to ordinary prescribing with Swissmedic licensing upstream.
15 May 2021
The amended Narcotics Act creates a legal basis for locality-bound, time-limited scientific pilot trials of regulated cannabis supply. The framework applies for ten years, to 14 May 2031.
Policy · 8 Jul 2026